ATLASCrescent Biopharma (CBIO) earnings date: Nov 5, 2026
Crescent Biopharma (CBIO) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026. Analysts expect EPS of -$0.72.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on CBIO
| Last price | $12.78 (-5.2%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.2% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Crescent Biopharma stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Crescent Biopharma reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Crescent Biopharma. You can switch it off at any time.
Alert me before CBIO reportsFree to start. Creating an account takes under a minute.
Notify me when Crescent Biopharma reports
Track CBIO free Add Crescent Biopharma to a free ATLAS watchlist and see its next report date in one place.
CBIO earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.72 |
| Last report | Jul 30, 2026 · Beat |
| Beat rate (last 5 reports) | 4 of 5 (80%) |
| Average EPS surprise | +20.9% |
| Average move around a report | ±8.8% (last 5) |
| Sector | Healthcare · Biotechnology |
Crescent Biopharma earnings history: last 5 reports
Crescent Biopharma last reported on Jul 30, 2026: EPS of -$0.62 against an estimate of -$0.64 (+3.1% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Jul 30, 2026 | -$0.64 | -$0.62 | +3.1% | Beat | -2.0% |
| Jun 9, 2026 | $0.48 | $0.22 | -54.2% | Miss | +1.7% |
| Apr 29, 2026 | -$0.95 | -$0.70 | +26.3% | Beat | -6.6% |
| Mar 27, 2026 | -$3.78 | -$0.97 | +74.3% | Beat | +23.1% |
| Mar 17, 2026 | $0.42 | $0.65 | +54.8% | Beat | -10.6% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for CBIO
See the fair value, the probability range and the earnings history of Crescent Biopharma on its ATLAS page.
Crescent Biopharma (CBIO) stock analysisPlans from €3.99 a month.
Crescent Biopharma earnings: frequently asked questions
When does Crescent Biopharma (CBIO) report earnings?
Crescent Biopharma is scheduled to report on Thursday, November 5, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for CBIO?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.72 per share (USD). Estimates can change before the report.
How often does CBIO beat earnings estimates?
Of its last 5 reports with a recorded result, Crescent Biopharma beat the EPS estimate 4 times; the average surprise was +20.9%. Past results do not predict the next one.
How much does CBIO move around earnings?
Over its last 5 reports the stock moved an average of 8.8% (absolute, from the close before the report day to the close after it), and finished higher 2 of 5 times.
Did Crescent Biopharma beat earnings estimates last quarter?
Crescent Biopharma last reported on Jul 30, 2026: EPS of -$0.62 against an estimate of -$0.64 (+3.1% surprise), a beat.
How much does CBIO usually move in a day?
On a normal trading day the ATLAS model puts CBIO’s one-day range at about ±4.2%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer